Autonomix Medical, Inc. Common Stock (AMIX) - Net Assets
Based on the latest financial reports, Autonomix Medical, Inc. Common Stock (AMIX) has net assets worth $3.16 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($3.98 Million) and total liabilities ($818.00K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. See Autonomix Medical, Inc. Common Stock (AMIX) balance sheet quality index to measure how much of total assets are equity-financed.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $3.16 Million |
| % of Total Assets | 79.45% |
| Annual Growth Rate | 31.7% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 483.01 |
Autonomix Medical, Inc. Common Stock - Net Assets Trend (2022–2026)
This chart illustrates how Autonomix Medical, Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see AMIX company net worth.
Annual Net Assets for Autonomix Medical, Inc. Common Stock (2022–2026)
The table below shows the annual net assets of Autonomix Medical, Inc. Common Stock from 2022 to 2026. Also explore net asset growth rate of Autonomix Medical, Inc. Common Stock to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2026-03-31 | $5.89 Million | -27.21% |
| 2025-03-31 | $8.10 Million | +6.17% |
| 2024-03-31 | $7.63 Million | +1084.47% |
| 2023-03-31 | $644.00K | -67.13% |
| 2022-03-31 | $1.96 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Autonomix Medical, Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 4554101200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (March 2026)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $11.00K | 0.19% |
| Other Components | $72.98 Million | 1237.96% |
| Total Equity | $5.89 Million | 100.00% |
Autonomix Medical, Inc. Common Stock Competitors by Market Cap
The table below lists competitors of Autonomix Medical, Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Rare Earth Magnesium Technology Group Holdings Limited
STU:GPS
|
$4.16 Million |
|
Lion Energy Ltd
AU:LIO
|
$4.16 Million |
|
Mears Group plc
LSE:MER
|
$4.16 Million |
|
Moleculin Biotech Inc
NASDAQ:MBRX
|
$4.16 Million |
|
Aruma Resources Ltd
AU:AAJ
|
$4.15 Million |
|
Golden Sky Minerals Corp
V:AUEN
|
$4.15 Million |
|
Aston Martin Lagonda Global Holdings PLC
LSE:AML
|
$4.14 Million |
|
VVC Exploration Corp.
V:VVC
|
$4.14 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Autonomix Medical, Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2025 to 2026, total equity changed from 8,099,000 to 5,895,000, a change of -2,204,000 (-27.2%).
- Net loss of 16,715,000 reduced equity.
- New share issuances of 3,531,000 increased equity.
- Other factors increased equity by 10,980,000.
Equity Change Factors (2025 to 2026)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-16.71 Million | -283.55% |
| Share Issuances | $3.53 Million | +59.9% |
| Other Changes | $10.98 Million | +186.26% |
| Total Change | $- | -27.21% |
Book Value vs Market Value Analysis
This analysis compares Autonomix Medical, Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.25x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.10x to 0.25x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-03-31 | $43.79 | $4.28 | x |
| 2023-03-31 | $14.39 | $4.28 | x |
| 2024-03-31 | $170.00 | $4.28 | x |
| 2025-03-31 | $96.28 | $4.28 | x |
| 2026-03-31 | $17.15 | $4.28 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Autonomix Medical, Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -283.55%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.29x
- Recent ROE (-283.55%) is above the historical average (-323.17%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | -680.21% | 0.00% | 0.00x | 1.05x | $-13.52 Million |
| 2023 | -309.01% | 0.00% | 0.00x | 1.34x | $-2.05 Million |
| 2024 | -202.23% | 0.00% | 0.00x | 1.23x | $-16.19 Million |
| 2025 | -140.88% | 0.00% | 0.00x | 1.21x | $-12.22 Million |
| 2026 | -283.55% | 0.00% | 0.00x | 1.29x | $-17.30 Million |
Industry Comparison
This section compares Autonomix Medical, Inc. Common Stock's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $709,562,588
- Average return on equity (ROE) among peers: -60.94%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Autonomix Medical, Inc. Common Stock (AMIX) | $3.16 Million | -680.21% | 0.26x | $4.16 Million |
| Abbott Laboratories (ABT) | $4.40 Billion | 38.41% | 1.14x | $177.76 Billion |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $12.40 Million | -202.26% | 2.49x | $11.55 Million |
| Aethlon Medical Inc (AEMD) | $-9.30 Million | 0.00% | 0.00x | $1.11 Million |
| Acutus Medical Inc (AFIB) | $-131.82 Million | 0.00% | 0.00x | $903.35K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $780.04 Million |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $1.53 Million | -361.86% | 1.36x | $4.88 Million |
| Allurion Technologies, Inc. (ALUR) | $-32.31 Million | 0.00% | 0.00x | $1.19 Million |
| Artivion Inc (AORT) | $79.80 Million | -34.79% | 0.33x | $1.16 Billion |
| Apyx Medical Inc (APYX) | $2.22 Million | 4.46% | 0.72x | $127.64 Million |
About Autonomix Medical, Inc. Common Stock
Autonomix Medical, Inc., a development stage medical device company, focuses on advancing technologies for sensing and treating disorders of nervous system. The company's technology platform includes a catheter-based system incorporating microchip-enabled sensing architecture designed to detect low-amplitude neural signals from within the vascular system. It develops technology for patients with … Read more